Phathom Pharmaceuticals (PHAT) Enterprise Value (2022 - 2025)
Phathom Pharmaceuticals (PHAT) has disclosed Enterprise Value for 4 consecutive years, with -$132.8 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 55.31% to -$132.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$132.8 million, a 55.31% increase, with the full-year FY2025 number at -$132.8 million, up 55.31% from a year prior.
- Enterprise Value was -$132.8 million for Q4 2025 at Phathom Pharmaceuticals, up from -$138.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$130.1 million in Q1 2023 to a low of -$384.3 million in Q4 2023.
- A 4-year average of -$222.0 million and a median of -$210.1 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: crashed 149.92% in 2024, then soared 59.11% in 2025.
- Phathom Pharmaceuticals' Enterprise Value stood at -$155.9 million in 2022, then plummeted by 146.49% to -$384.3 million in 2023, then increased by 22.64% to -$297.3 million in 2024, then skyrocketed by 55.31% to -$132.8 million in 2025.
- Per Business Quant, the three most recent readings for PHAT's Enterprise Value are -$132.8 million (Q4 2025), -$138.0 million (Q3 2025), and -$149.6 million (Q2 2025).